Xylo is a biotech startup that is using computational methods and rigorous medicinal chemistry to design novel brain drugs to treat mental health and neurological disorders by rewiring neural circuits and restoring brain function. Many of their drug candidates are inspired by naturally occurring psychedelic drugs, but are specifically designed to not induce hallucinations.
Xylo's cofounders Josh Ismin and Sam Banister join Brom Rector and Sam Tabone to discuss:
3:25 - Xylo origins + why design novel psychedelic molecules?
10:30 - How Xylo’s AI approach is different than other non-hallucinogenic psychedelic companies like Gilgamesh and Delix
21:30 - What is the head twitch response?
25:30 - How Xylo’s drugs are different than other psychedelics even though they hit the same receptor (5HT2a)
26:30 - How Lykos’ failure to get MDMA approved impacts Xylo
32:00 - Running trials in Australia
43:00 - How has Xylo has evolved over the years
50:30 - How will AI change drug discovery
53:00 - How much of the neuro receptor space has been characterized
56:00 - Is Xylo bullish or bearish on AI
More on Xylo here: https://www.xylo.bio/
Stay up to date on Human 3 - the new epoch of health, wellbeing and performance